Objective: To investigate whether LY01008, a locally developed bevacizumab biosimilar agent, is appropriate for widespread use among Chinese advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC) patients, our current study was designed to evaluate the cost-effectiveness of first-line LY01008 combined with platinum-doublet chemotherapy versus chemotherapy alone from the perspective of the Chinese healthcare system.Material and Methods: This economic evaluation designed a Markov model to compare the healthcare cost and quality-adjusted life-year (QALY) of first-line LY01008 combined with chemotherapy versus first-line chemotherapy. Transition probabilities, including disease progression, survival, and adverse event (AE)-related...
INTRODUCTION:Anaplastic lymphoma kinase (ALK) rearrangement gene testing is used increasingly to ide...
Objective: Sugemalimab is approved in China as a first-line treatment in combination with chemothera...
Objective: Our previous economic assessment found that nivolumab was not cost-effective for Chinese ...
Objective: To investigate whether LY01008, a locally developed bevacizumab biosimilar agent, is appr...
AIMS: The aim of this analysis is to investigate the mean incremental costs and life expectancy asso...
The aim of the study was to evaluate the cost-effectiveness of adding atezolizumab to first-line che...
AbstractObjectivesBevacizumab is approved for treatment of advanced non-small cell lung cancer (NSCL...
Introduction: The new targeted agent bevacizumab in combination with cisplatin and gemcitabine (BCG)...
Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherap...
Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherap...
Objective: To investigate the cost-effectiveness of adding Chinese-developed anti-PD-1 antibody tisl...
Abstract Objective The objective of this study is to evaluate the cost-effectiveness of adding pembr...
Abstract Objective In frst-line treatment of advanced or metastatic nonsquamous non-small-cell lung ...
Purpose: Pembrolizumab was recently approved in several countries as a first-line treatment for pati...
The aim of the current study was to evaluate the cost-effectiveness of serplulimab plus chemotherapy...
INTRODUCTION:Anaplastic lymphoma kinase (ALK) rearrangement gene testing is used increasingly to ide...
Objective: Sugemalimab is approved in China as a first-line treatment in combination with chemothera...
Objective: Our previous economic assessment found that nivolumab was not cost-effective for Chinese ...
Objective: To investigate whether LY01008, a locally developed bevacizumab biosimilar agent, is appr...
AIMS: The aim of this analysis is to investigate the mean incremental costs and life expectancy asso...
The aim of the study was to evaluate the cost-effectiveness of adding atezolizumab to first-line che...
AbstractObjectivesBevacizumab is approved for treatment of advanced non-small cell lung cancer (NSCL...
Introduction: The new targeted agent bevacizumab in combination with cisplatin and gemcitabine (BCG)...
Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherap...
Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherap...
Objective: To investigate the cost-effectiveness of adding Chinese-developed anti-PD-1 antibody tisl...
Abstract Objective The objective of this study is to evaluate the cost-effectiveness of adding pembr...
Abstract Objective In frst-line treatment of advanced or metastatic nonsquamous non-small-cell lung ...
Purpose: Pembrolizumab was recently approved in several countries as a first-line treatment for pati...
The aim of the current study was to evaluate the cost-effectiveness of serplulimab plus chemotherapy...
INTRODUCTION:Anaplastic lymphoma kinase (ALK) rearrangement gene testing is used increasingly to ide...
Objective: Sugemalimab is approved in China as a first-line treatment in combination with chemothera...
Objective: Our previous economic assessment found that nivolumab was not cost-effective for Chinese ...